Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction

Hematology

Volumn 18, Issue 6, 2013, Pages 341-347

  Gao, Wen ^a   Geng, Chuanying ^a   Zhang, Lei ^a   Li, Yanchen ^a   Chen, Wenming ^a   Wang, Chen ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Myeloma; Novel therapy; Outcome; Stem cell transplant

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CASE STUDY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSOLIDATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; FATIGUE; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; INDUCTION CHEMOTHERAPY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PYREXIA IDIOPATHICA; RASH; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; COMBINED MODALITY THERAPY; CONSOLIDATION CHEMOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84885794325     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845413Y.0000000082     Document Type: Article

References (22)

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111: 2516-20.
2. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012;9: 135-43.
3. Moreau P, Avet-Loiseau H, Harousseau JL, Attal M. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol. 2011;29:1898-906.
4. Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev Hematol. 2011;4:51-60.
5. Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, et al. Current multiple myeloma treatment strategies with novel agents: an European perspective. Oncologist. 2010;15: 6-25.
6. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-7.
7. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. Medical Research Council Adult Leukaemia Working Party: high dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-83.
8. Van de Velde HJK, Liu X, Chen G, Cakana A, Draedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92:1399-406.
9. Lahuerta JJ, Mateos MV, Martinez-Lopez J, Rosiñol L, Sureda A, de la Rubia J, et al. Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26:5775-82.
10. Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med. 2009; 360:2645-54.
11. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia. 2009;23:449-56.
12. Bensinger W. Stem-cell transplantatin for multiple myeloma in the era of novel drugs. J Clin Oncol. 2008;26:480-92.
13. Kumar S. Multiple myeloma-current issues and controversies. Cancer Treat Rev. 2010;36(Suppl 2):S3-11.
14. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, et al. International Myeloma Working Group: International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117: 6063-73.
15. Engelhardt M, Kleber M, Udi J, Wäsch R, Spencer A, Patriarca F, et al. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma. 2010; 51:1424-43.
16. Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005;106: 3755-9.
17. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28:4621-9.
18. Popat R, Oakervee HE, Hallam S, Curry N, Odeh L, Foot N, et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol. 2008;141:512-6.
19. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129:755-62.
20. Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Cancer. 2010;116:3143-51.
21. Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, et al. Brtezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011; 118:5752-8.
22. Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120:9-12.